Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced data from a new dissection characterizing the effects of SYMLIN® (pramlintide acetate) injection in billet with type 1 insulin-dependent insulin-dependent diabetes mellitus mellitus who used insulin pumps during two time was completed clinical studies. The data, which will be presented during a poster introduction at the 71st Scientific Sessions of the old glory insulin-dependent insulin-dependent diabetes mellitus mellitus troops (ADA) in San Diego, demonstrated that SYMLIN helped reduce A1C (a measure of average blood sugar over three months), insulin use and body weight in work with type 1 type i insulin-dependent diabetes mellitus who used insulin pumps...

More: - From the site